Congress Materials

Medical Information
Ireland
 

In order to provide you with relevant and meaningful content we need to know more about you.

Please choose the category that best describes you.

This content is intended for U.S. Healthcare Professionals. Would you like to proceed?

I am a healthcare professionalYes, I am a healthcare professional
SelectI am a healthcare professionalYes, I am a healthcare professional
I am a Patient/Caregiver or
Member of the General PublicNo, go back to the patient portal
SelectI am a Patient/Caregiver or
Member of the General PublicNo, go back to the patient portal

If you don't reside in Ireland, please click here

The medical information on this site is intended only for healthcare professionals in the Republic of Ireland. The products discussed herein may have different product labeling in other countries.

This information is not intended as medical advice. Responsibility for patient care resides with the healthcare professional on the basis of his or her professional license, experience and knowledge of the patient.

Congress Materials

The information on this page pertains to select congresses, congress materials, therapeutic and disease areas. It is not intended to serve as a comprehensive overview of all congresses, congress materials, therapeutic and disease areas.
Congress materials may include information for which the product is not approved and/or inconsistent with the product uses described in the Prescribing Information. Pfizer does not suggest or recommend the use of Pfizer Products in any manner other than as described in the Prescribing Information.
Oral Presentation
Turner N, Marmé F, Kim S-B, Bonnefoi H, García-Sáenz JA, Torres AA, Bear H, Tesch H, Olivé MM, McCarthy N, Jurado JC, Im S-A, Liu Y, Zhang Z, Weber K, Felder B, Nekljudova V, Reimer T, Denkert C, Loibl S June 2, 2023 ASCO 2023 Breast Cancer

Detection of Circulating Tumor DNA Following Neoadjuvant Chemotherapy and Surgery to Anticipate Early Relapse in ER Positive and HER2 Negative Breast Cancer, Analysis From the PENELOPE-B Trial

View Presentation
Poster
Drilon A, Johnson ML, Gadgeel S, Nepert D, Feng G, Golmakani M, Reddy MB, Harney AS, Oliver C, Mills B, Therond J, Rothenberg SM, Sharma MR, Yap TA June 3, 2023 ASCO 2023 Other/Multi-Tumor

A First-in-Human, Phase 1 Study of the SHP2 Inhibitor PF-07284892 as Monotherapy and in Combination With Different Targeted Therapies in Oncogene-Driven Treatment-Resistant Solid Tumors

View Presentation View Abstract Plain Language Summary
Poster
Beck T, McKean M, Gadgeel S, Bowles DW, Haq R, Yaeger R, Taylor M, Maity A, Drescher S, Oliver C, Huelskamp AM, Feng G, Sturtz K June 3, 2023 ASCO 2023 Other/Multi-Tumor

A Phase 1, Open-Label, Dose Escalation and Dose Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of PF-07799933 (ARRY-440) as a Single Agent and in Combination Therapy in Participants Aged 16 Years and Older With Advanced Solid Tumors With BRAF Alterations

View Presentation
Poster
Roth JA, Chaudhry BI, Yue A, Kelton JM, Shelbaya A, Tran L, Li M, Yang J June 3, 2023 ASCO 2023 Other/Multi-Tumor

An Assessment of the Provider Financial Risk Impacts of Adoption of Biosimilars in the Medicare Oncology Care Model

View Presentation
Poster
Costa LJ, LeBlanc TW, Tesch H, Sonneveld P, Kyle R, Sinyavskaya L, Hlavacek P, Meche A, Ren J, Schepart A, Aydin D, DiBonaventura M June 3, 2023 ASCO 2023 Hematology

An Indirect Comparison of Elranatamab’s (ELRA) Objective Response Rate (ORR) From MagnetisMM-3 (MM-3) vs Real-World External Control Arms in Triple-Class Refractory (TCR) Multiple Myeloma (MM)

View Presentation View Abstract Plain Language Summary
Poster
Friedrich NA, Janes JL, Parrish J, De Hoedt AM, Pruett J, Fallick M, Gandhi R, Zhu E, Morlock R, Freedland SJ June 3, 2023 ASCO 2023 Prostate Cancer

Assessing Racial Differences in Time to Treatment Escalation Following Androgen-Deprivation Therapy Among Veterans With Prostate Cancer

View Presentation
Oral Presentation
Nooka AK, Lesokhin AM, Mohty M, Niesvizky R, Maisel C, Arnulf B, Larson SM, Varshavsky-Yanovsky AN, Leleu X, Karlin L, Vesole DH, Bahlis NJ, de Larrea CF, Raje N, Leip E, Conte U, Elmeliegy M, Viqueira A, Manier S June 3, 2023 ASCO 2023 Hematology

Efficacy and Safety of Elranatamab in Patients With Relapsed/Refractory Multiple Myeloma and Prior B-cell Maturation Antigen (BCMA)-Directed Therapies: A Pooled Analysis From MagnetisMM Studies

View Presentation View Abstract Plain Language Summary
Poster
Schadendorf D, Dummer R, Robert C, Ribas A, Sullivan RJ, Panella T, Penkov K, Dudnichenko O, McKean M, Santos ES, Clancy J, Thakur MN, Polli A, di Pietro A, Ascierto PA June 3, 2023 ASCO 2023 Skin Cancer

Encorafenib + Binimetinib + Pembrolizumab for Unresectable Locally Advanced or Metastatic BRAF V600-Mutant Melanoma: Results From STARBOARD Safety Lead-in (SLI)

View Presentation View Abstract Plain Language Summary
Poster
Yap TA, Giordano A, Hamilton E, LoRusso P, Basu C, Billotte S, Delioukina M, Liu F, Yang J, Sharma MR June 3, 2023 ASCO 2023 Other/Multi-Tumor

First-in-Human First-in-Class Phase 1/2a Study of the Next Generation CDK4-Selective Inhibitor PF-07220060 in Patients With Advanced Solid Tumors, Enriched for HR+/HER2- mBC Patients Who Progressed on Prior CDK4/6 Inhibitors and Endocrine Therapy

View Presentation View Abstract Plain Language Summary
Poster
Yap TA, Elhaddad A, Grisham RN, Hamm J, Marks DK, Shapiro G, Le Corre C, Li J, Lin TT, Liu F, Malky L, Moreau A, Neumann H, Juric D, Sharma MR June 3, 2023 ASCO 2023 Other/Multi-Tumor

First-in-Human Phase 1/2a Study of a Potent and Novel CDK2-Selective Inhibitor PF-07104091 in Patients With Advanced Solid Tumors, Enriched for CDK4/6 Inhibitor-Resistant HR+/HER2- Breast Cancer Patients

View Presentation View Abstract Plain Language Summary